ViVitro Heart Valve AWT System with Dual Control Technology (DCT™) at TCT 2023

October 23rd, 2023

Heart Valve AWT System with DCT™

“Maintains constant leaflet closing velocities during the entire AWT cycling period and reduces costly false negative results generated by heart valve prothesis fatigue test systems without Dual Control Technology.”

VICTORIA, BC, October 23, 2023 /PRNewswire/ — ViVitro Labs announces a new generation Accelerated Wear Testing (AWT) System to efficiently mitigate variable leaflet closing velocity test artifacts associated with first- and second-generation systems. ViVitro will showcase the ViVitro Heart Valve Accelerated Wear Testing System  with DCT™ (Dual Control Technology), at TCT 2023 in booth 348 on October 24 – 26, 2023, at the Moscone Center in San Francisco, CA. The revolutionary self-regulating AWT system reduces false negative results generated by most heart valve fatigue testing systems.

Variable leaflet closing velocities of heart valve prosthesis during the AWT cycling period is associated with premature wear and over testing of perfectly sound valve designs. This test artifact can have a detrimental impact on R&D cost and development timelines.

The ViVitro AWT System with DCT™ wowed attendees during a sneak preview at TCT in September 2022, garnering record-breaking demand. Since TCT 2022, the ViVitro AWT System with DCT™ has undergone extensive system performance evaluation in various normal and severe test conditions to pass ViVitro’s verification and validation requirements. ViVitro will be accepting new orders at and after TCT.

Karim Mouneimne, President of ViVitro Labs Inc., explains how Dual Control Technology regulates test conditions and stabilizes leaflet closing velocities during AWT.

The ViVitro AWT System with Dual Control Technology (DCTTM) is an innovation in fatigue testing of heart valve prosthesis that will help valve developers push the envelope of medical device technology.  

The ViVitro AWT System with DCTTM uses two separate position feedback sensors and algorithms to maintain constant leaflet closing velocities across the entire AWT cycling period.

Piston displacement and bypass valve position are controlled independently to meet differential pressure requirements while preserving initial leaflet closing velocities. The combined action of both feedback sensors forms our Dual Control Technology, DCT”.

ViVitro AWT system performance improvements and enhancements since its TCT 2022 preview include:

  • Simplified DCT™ User Interface and Optimization of 5% Rule
  • Improved interchangeability of parts
  • Increased system physical robustness
  • Enhanced filtering systems and immunity on pressure signals inputs
  • Advanced motor current monitoring
  • Further system noise reduction
  • Optimized system thermal management

About TCT 2023

For more than three decades, TCT has ignited innovation, education, and connection in interventional cardiology, with the purpose of improving the survival and quality of life of patients suffering from heart and vascular disease. TCT 2023 will host 11,000+ Attendees, 5,000+ Physicians from 100+ Countries on October 24 – 26, 2023, at the Moscone Center in San Francisco, CA.

About ViVitro Labs

ViVitro Labs Inc., Canada, offers industry-leading cardiovascular test equipment and related laboratory testing and consulting services. We are the trusted partner for scalable and modular test equipment solutions through continuous innovation, and de-risking the cardiovascular device development process through repeatable and reproducible validated test methods.

ViVitro Labs management and employees bring a wealth of experience and technical expertise in cardiovascular device testing, test equipment and test method development.  We provide our clients sustainable and reliable engineering solutions that further research projects and advance medical device development.

Hundreds of organizations in over 39 countries for 35 years have trusted ViVitro expertise, reliability, and quality in testing heart valves, LVAD, interventional devices, stent, and stent-graft. ViVitro Laboratory Services have two ISO/IEC 17025 accredited laboratories (see our ISO 17925 scope of accreditation for Marseille, France and Victoria, Canada). ViVitro Labs products are manufactured by StarFish Medical in Victoria, Canada.

CONTACT: ViVitro Labs Inc., Douglas Bigrigg, Business Development Manager, +1 (250) 940 2446


    Join over 5000 cardiovascular device professionals who receive our testing and engineering insights and tips every month.